Proactive Investors - Run By Investors For Investors

Tissue Regenix boss to return to full-time duties in June

Steve Couldwell has been out of action so far this year while he undergoes medical treatment
Steve Couldwell
Despite Couldwell’s absence, TRX has “continued to develop in line with expectations”

The chief executive of Tissue Regenix Group PLC (LON:TRX) is to return to full-time duties next month.

At the end of last year, the regenerative medicines specialist confirmed Steve Couldwell would be taking a temporary leave of absence to undergo medical treatment.

READ: Tissue Regenix secures additional coverage for DermaPure from US GPO

“The board and I look forward to welcoming Steve back into the full time CEO position and are grateful for his ongoing commitment,” said chairman John Samuel, who held the fort whilst Couldwell was away.

“During his necessary absence Steve remained in daily contact with the business and continued to be integral to implementing the business strategy and establishing future business developments, along with the support of Gareth Jones who undertook the chief operating officer role during this period.”

Samuel added: “The business has continued to develop in line with the board expectations.”

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

tablets and pills
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use